These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 31949048)

  • 1. A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.
    Sarkar SK; Foo ACY; Matyas A; Asikhia I; Kosenko T; Goto NK; Vergara-Jaque A; Lagace TA
    J Biol Chem; 2020 Feb; 295(8):2285-2298. PubMed ID: 31949048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.
    Susan-Resiga D; Girard E; Kiss RS; Essalmani R; Hamelin J; Asselin MC; Awan Z; Butkinaree C; Fleury A; Soldera A; Dory YL; Baass A; Seidah NG
    J Biol Chem; 2017 Feb; 292(5):1573-1590. PubMed ID: 27998977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
    Galvan AM; Chorba JS
    J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.
    Kosenko T; Golder M; Leblond G; Weng W; Lagace TA
    J Biol Chem; 2013 Mar; 288(12):8279-8288. PubMed ID: 23400816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of amino acid residues in the ligand binding repeats of LDL receptor important for PCSK9 binding.
    Deng SJ; Alabi A; Gu HM; Adijiang A; Qin S; Zhang DW
    J Lipid Res; 2019 Mar; 60(3):516-527. PubMed ID: 30617148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
    Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
    J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
    Lu X
    Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor.
    Holla ØL; Laerdahl JK; Strøm TB; Tveten K; Cameron J; Berge KE; Leren TP
    Biochem Biophys Res Commun; 2011 Mar; 406(2):234-8. PubMed ID: 21324305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
    Guo S; Xia XD; Gu HM; Zhang DW
    Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding.
    Sarkar SK; Matyas A; Asikhia I; Hu Z; Golder M; Beehler K; Kosenko T; Lagace TA
    Front Physiol; 2022; 13():960272. PubMed ID: 36187800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Helical Segment within the Intrinsically Disordered Region of the PCSK9 Prodomain.
    Ultsch M; Li W; Eigenbrot C; Di Lello P; Lipari MT; Gerhardy S; AhYoung AP; Quinn J; Franke Y; Chen Y; Kong Beltran M; Peterson A; Kirchhofer D
    J Mol Biol; 2019 Mar; 431(5):885-903. PubMed ID: 30653992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor.
    Garvie CW; Fraley CV; Elowe NH; Culyba EK; Lemke CT; Hubbard BK; Kaushik VK; Daniels DS
    Protein Sci; 2016 Nov; 25(11):2018-2027. PubMed ID: 27534510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9.
    Sánchez-Hernández RM; Di Taranto MD; Benito-Vicente A; Uribe KB; Lamiquiz-Moneo I; Larrea-Sebal A; Jebari S; Galicia-Garcia U; Nóvoa FJ; Boronat M; Wägner AM; Civeira F; Martín C; Fortunato G
    Atherosclerosis; 2019 Oct; 289():162-172. PubMed ID: 31518966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
    Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
    J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Insights into Protein-protein Interaction Disruptive Mutations in the PCSK9-LDLR complex.
    Martin WR; Lightstone FC; Cheng F
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
    Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
    J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.